Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?

被引：14

作者：

Wong, Grace Lai-Hung ^{[1
,2
]}

Lampertico, Pietro ^{[3
]}

机构：

[1] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Dept Med, Hong Kong, Peoples R China

[3] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, CRC AM & A Migliavacca Ctr Study Liver Dis, Div Gastroenterol & Hepatol, Via F Sforza 35, I-20122 Milan, Italy

来源：

JOURNAL OF HEPATOLOGY | 2019年 / 71卷 / 03期

关键词：

HEPATITIS-B; ENTECAVIR;

D O I：

10.1016/j.jhep.2019.05.017

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：453 / 455

页数：3

共 16 条

[1] Antitumor activity of Type I and Type III interferons in BNL hepatoma model
Abushahba, Walid
Balan, Murugabaskar
Castaneda, Ismael
Yuan, Yao
Reuhl, Kenneth
Raveche, Elizabeth
de la Torre, Andrew
Lasfar, Ahmed
Kotenko, Sergei V.
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (07) : 1059 - 1071
[2] Negative Controls to Detect Selection Bias and Measurement Bias in Epidemiologic Studies
Arnold, Benjamin F.
Ercumen, Ayse
Benjamin-Chung, Jade
Colford, John M., Jr.
[J]. EPIDEMIOLOGY, 2016, 27 (05) : 637 - 641
[3] RETRACTED: Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study (Retracted Article)
Choi, Jonggi
Kim, Hyo Jeong
Lee, Jayoun
Cho, Songhee
Ko, Min Jung
Lim, Young-Suk
[J]. JAMA ONCOLOGY, 2019, 5 (01) : 30 - 36
[4] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico P.
Agarwal K.
Berg T.
Buti M.
Janssen H.L.A.
Papatheodoridis G.
Zoulim F.
Tacke F.
[J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
[5] Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B One of These Things Is Not Like the Other
Flemming, Jennifer A.
Terrault, Norah A.
[J]. JAMA ONCOLOGY, 2019, 5 (01) : 17 - 18
[6] Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a US Cohort
Gordon, Stuart C.
Zhou, Yueren
Li, Jia
Rupp, Loralee B.
Boscarino, Joseph A.
Daida, Yihe G.
Schmidt, Mark A.
Trudeau, Sheri
Lu, Mei
[J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E147 - E147
[7] A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea
Kim, Seung Up
Seo, Yeon Seok
Lee, Han Ah
Kim, Mi Na
Lee, Yu Rim
Lee, Hye Won
Park, Jun Yong
Kim, Do Young
Ahn, Sang Hoon
Han, Kwang-Hyub
Hwang, Seong Gyu
Rim, Kyu Sung
Um, Soon Ho
Tak, Won Young
Kweon, Young Oh
Kim, Beom Kyung
Park, Soo Young
[J]. JOURNAL OF HEPATOLOGY, 2019, 71 (03) : 456 - 464
[8] Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients
Koike, Kazuhiko
Suyama, Kazuaki
Ito, Hiroshi
Itoh, Hiroshi
Sugiura, Wataru
[J]. HEPATOLOGY RESEARCH, 2018, 48 (01) : 59 - 68
[9] The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study
Lampertico, Pietro
Invernizzi, Federica
Vigano, Mauro
Loglio, Alessandro
Mangia, Giampaolo
Facchetti, Floriana
Primignani, Massimo
Jovani, Manol
Iavarone, Massimo
Fraquelli, Mirella
Casazza, Giovanni
de Franchis, Roberto
Colombo, Massimo
[J]. JOURNAL OF HEPATOLOGY, 2015, 63 (05) : 1118 - 1125
[10] Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
Murata, Kazumoto
Asano, Mai
Matsumoto, Akihiro
Sugiyama, Masaya
Nishida, Nao
Tanaka, Eiji
Inoue, Taisuke
Sakamoto, Minoru
Enomoto, Nobuyuki
Shirasaki, Takayoshi
Honda, Masao
Kaneko, Shuichi
Gatanaga, Hiroyuki
Oka, Shinichi
Kawamura, Yuki I.
Dohi, Taeko
Shuno, Yasutaka
Yano, Hideaki
Mizokami, Masashi
[J]. GUT, 2018, 67 (02) : 362 - 371

← 1 2 →